Skip to content

US · PTN · BIOTECHNOLOGY

Palatin Technologies, Inc. (PTN) intrinsic value and stock valuation

$4.58as of 2026-11-21 · Mkt cap 13.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Palatin Technologies, Inc. DCF and intrinsic value

InvestorsCraft values PTN with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from PTN’s statements →

Palatin Technologies, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Monmouth Junction, NJ 08512 palatin.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-17.31M
20112025
Free cash flow
-$-21.31M
20112025
Total equity
-$-4.78M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$4.49M$4.85M$1.47M-$-190K
Operating income-$-17.46M-$-22.5M-$-32.46M-$-36.59M-$-33.38M
Net income-$-17.31M-$-29.74M-$-24.04M-$-36.2M-$-33.57M
EPSd-$-32.06M-$-2.02M-$-2.21M-$-3.79M-$-3.54M
Operating cash flow-$-21.31M-$-31.46M-$-28.42M-$-29.92M-$-22.65M
Capital expenditure-$0.00-$-40K-$-430K-$-260K-$-10K
Free cash flow-$-21.31M-$-31.5M-$-28.85M-$-30.18M-$-22.65M
Total assets$3.27M$10.7M$17.9M$36.1M$67.3M
Total debt$160K$590K$1.05M$1.15M$1.25M
Net debt-$-2.4M-$-8.94M-$-6.94M-$-28.79M-$-58.85M
Total equity-$-4.78M-$-110K-$-1.98M$16.3M$49.7M
Cash and short-term investments$2.56M$9.53M$11M$29.9M$60.1M
Income statement
20252024202320222021
Revenue$0.00$4.49M$4.85M$1.47M-$-190K
Cost of revenue$0.00$100K$420K$220K$150K
Gross profit$0.00$4.39M$4.44M$1.25M-$-340K
Research and development expenses$14.9M$22.4M$22.6M$21.3M$12.9M
Selling, general and administrative expenses$7.81M$12.3M$15.3M$16.5M$17.3M
Other expenses-$-5.25M-$-7.78M-$-1.03M$0.00$2.78M
Operating expenses$17.5M$26.9M$36.9M$37.8M$33.1M
Cost and expenses$17.5M$27M$37.3M$38.1M$33.2M
Interest income$0.00$0.00$0.00$0.00$20K
Interest expense$20K$20K$20K$30K$0.00
Depreciation and amortization$260K$340K$290K$490K$50K
Ebitda-$-17.03M-$-29.38M-$-28.4M-$-35.68M-$-33.52M
Operating income-$-17.46M-$-22.5M-$-32.46M-$-36.59M-$-33.38M
Total other income/expenses, net$150K-$-7.24M$3.75M$390K-$-210K
Income before tax-$-17.31M-$-29.74M-$-28.71M-$-36.2M-$-33.6M
Income tax expense$0.00$0.00-$-4.67M$0.00$0.00
Net income-$-17.31M-$-29.74M-$-24.04M-$-36.2M-$-33.57M
Weighted average shares outstanding$540K$14.7M$10.9M$9.54M$9.47M
Weighted average diluted shares outstanding$540K$14.7M$10.9M$9.54M$9.47M
Balance sheet
20252024202320222021
Cash and short-term investments$2.56M$9.53M$11M$29.9M$60.1M
Net receivables$30K$0.00$2.92M$1.78M$1.58M
Inventory$0.00$0.00$530K$940K$1.16M
Total current assets$2.92M$9.77M$16.3M$34.6M$65.9M
Property, plant and equipment, net$290K$920K$1.56M$1.42M$1.33M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$350K$970K$1.62M$1.47M$1.39M
Total assets$3.27M$10.7M$17.9M$36.1M$67.3M
Accounts payable$7M$4.1M$4.3M$3.16M$640K
Short-term debt$130K$430K$460K$470K$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.01M$9.66M$15.1M$16.3M$10.5M
Long-term debt$30K$160K$590K$680K$900K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$30K$1.2M$4.79M$3.54M$7.13M
Capital lease obligations$160K$590K$1.05M$1.15M$1.25M
Total liabilities$8.04M$10.9M$19.9M$19.8M$17.7M
Common stock$10K$180K$120K$90K$90K
Retained earnings-$-459.07M-$-441.77M-$-412.03M-$-387.99M-$-351.8M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00-$0.00
Total equity-$-4.78M-$-110K-$-1.98M$16.3M$49.7M
Total investments$0.00$0.00$2.99M$0.00$0.00
Total debt$160K$590K$1.05M$1.15M$1.25M
Net debt-$-2.4M-$-8.94M-$-6.94M-$-28.79M-$-58.85M
Cash flow statement
20252024202320222021
Net income-$-17.31M-$-29.74M-$-27.54M-$-36.2M-$-33.6M
Depreciation and amortization$260K$340K$290K$130K$50K
Stock-based compensation$1.38M$1.87M$1.41M$2.51M$3.17M
Change in working capital-$-760K-$-3.41M-$-2.35M$3.44M-$-11.9M
Accounts receivable-$-30K$2.92M-$-1.14M-$-200K-$-1.58M
Inventory$0.00-$-1.15M$420K$220K-$-990K
Accounts payable$2.9M-$-200K$1.11M$2.57M-$-80K
Net cash provided by operating activities-$-21.31M-$-31.46M-$-28.42M-$-29.92M-$-22.65M
Investments in property, plant and equipment$0.00-$-40K-$-430K-$-260K-$-10K
Acquisitions, net$3.13M$9.5M$0.00$0.00$0.00
Net cash used for investing activities$3.13M$12.5M-$-3.43M-$-260K-$-10K
Common stock issued$7.96M$14.7M$10.1M$0.00$0.00
Common stock repurchased$0.00$0.00$0.00-$-220K-$-90K
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$11.2M$20.6M$9.9M$20K-$-90K
Net change in cash-$-6.96M$1.54M-$-21.95M-$-30.17M-$-22.75M
Cash at end of period$2.56M$9.53M$7.99M$29.9M$60.1M
Operating cash flow-$-21.31M-$-31.46M-$-28.42M-$-29.92M-$-22.65M
Capital expenditure-$0.00-$-40K-$-430K-$-260K-$-10K
Free cash flow-$-21.31M-$-31.5M-$-28.85M-$-30.18M-$-22.65M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Palatin Technologies, Inc.

        Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

        CEO
        Carl Spana
        Employees
        29
        Beta
        -0.07

        Explore

        Frequently asked questions

        What is the intrinsic value of Palatin Technologies, Inc. (PTN)?

        InvestorsCraft does not currently publish an intrinsic value for PTN. How the IC value is calculated.

        Is PTN undervalued?

        InvestorsCraft does not publish an undervaluation signal for PTN at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.